Compare
BriaCell Therapeutics Corp. vs Immunic, Inc. vs Kiora Pharmaceuticals Inc vs Faeth Therapeutics, Inc.
| Latest fiscal year | BriaCell Therapeutics Corp. BCTX | Immunic, Inc. IMUX | Kiora Pharmaceuticals Inc KPRX | Faeth Therapeutics, Inc. FTH |
|---|---|---|---|---|
| Year ended | 2026-07-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | n/a |
| Revenue growth (YoY) | n/a | n/a | -100.0% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$34.90M | -$97.17M | -$10.84M | -$21.09M |
| EPS (Diluted) | -$6.97 | -$0.62 | -$2.64 | -$16.72 |
| Operating cash flow | -$28.65M | -$85.81M | -$9.96M | -$20.45M |
| Free cash flow | -$28.78M | -$85.97M | -$10.07M | -$20.47M |
| Cash & equivalents | $9.85M | $15.48M | $8.70M | $8.67M |
| Total assets | $23.58M | $24.05M | $24.25M | $22.90M |
| Total liabilities | n/a | $30.73M | $8.13M | $4.31M |
| Shareholders' equity | $15.56M | -$6.67M | $16.13M | $18.59M |
| Return on year-end equity | -224.3% | n/a | -67.2% | -113.4% |
| Shares outstanding | 8.71M | 90.15M | 3.76M | 1.26M |
Revenue, most recent five fiscal years
| Fiscal year | BriaCell Therapeutics Corp. | Immunic, Inc. | Kiora Pharmaceuticals Inc | Faeth Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $0 Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | n/a | $16.02M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | $0 Ended 2021-12-31 | n/a |